Hudson Portfolio Management’s AbbVie ABBV Stock Holding History

Hudson Portfolio Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$339K	Hold	1,560	–	–	0.29%	89
2025 Q4	$356K	Hold	1,560	–	–	0.31%	87
2025 Q3	$361K	Hold	1,560	–	–	0.32%	87
2025 Q2	$290K	Hold	1,560	–	–	0.27%	92
2025 Q1	$327K	Sell	1,560 -575	-27%	-$112K	0.31%	86
2024 Q4	$379K	Sell	2,135 -200	-9%	-$36.8K	0.37%	79
2024 Q3	$461K	Buy	+2,335	New	+$436K	0.45%	71
2023 Q4	$558K	Sell	3,600 -150	-4%	-$21.9K	0.6%	54
2023 Q3	$559K	Hold	3,750	–	–	0.64%	54
2023 Q2	$505K	Sell	3,750 -950	-20%	-$139K	0.55%	58
2023 Q1	$749K	Sell	4,700 -1,060	-18%	-$162K	0.84%	44
2022 Q4	$931K	Sell	5,760 -2,085	-27%	-$320K	1.03%	38
2022 Q3	$1.05M	Sell	7,845 -350	-4%	-$50.2K	1.24%	30
2022 Q2	$1.25M	Sell	8,195 -2,875	-26%	-$439K	1.3%	26
2022 Q1	$1.79M	Sell	11,070 -5,650	-34%	-$821K	1.58%	20
2021 Q4	$2.26M	Sell	16,720 -150	-0.9%	-$17.7K	2%	14
2021 Q3	$1.82M	Sell	16,870 -100	-0.6%	-$11.4K	1.68%	16
2021 Q2	$1.91M	Hold	16,970	–	–	1.76%	17
2021 Q1	$1.84M	Buy	+16,970	New	+$1.82M	1.77%	15

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Hudson Portfolio Management's ABBV Position: Q1 2026 in Review

Hudson Portfolio Management held its AbbVie (ABBV) position steady in Q1 2026 at 1,560 shares worth $339K. The position accounts for 0.29% of the portfolio, ranked #89.

Hudson Portfolio Management first reported a position in ABBV in Q1 2021 and has held it in 19 quarters since. The position peaked at $2.26M in Q4 2021. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Hudson Portfolio Management held 1,560 shares of AbbVie worth $339K as of Q1 2026.
Hudson Portfolio Management left its AbbVie share count unchanged in Q1 2026.
AbbVie made up 0.29% of Hudson Portfolio Management's portfolio in Q1 2026, its #89 holding.
Hudson Portfolio Management first reported a position in AbbVie in Q1 2021 and has held it in 19 quarters since.
Hudson Portfolio Management's AbbVie position peaked at $2.26M in Q4 2021.
4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Hudson Portfolio Management's 13F filing for Q1 2026, filed 14 May 2026.